Depression in adolescence may be shaped by biological signals traveling between the gut and the brain, according to a new review published in Translational Psychiatry. The article, led by Zi, Liu, Zhou and colleagues, examines how disturbances in the gut microbiota may be connected to depressive symptoms during a period of rapid neurological, hormonal and immune development. Rather than treating the gut as a passive digestive system, the researchers present it as an active communication hub that may influence mood, stress responses and brain development.
Adolescent depression is a major public health concern, affecting emotional wellbeing, academic performance, relationships and long-term health. The teenage years are marked by extensive remodeling of neural circuits, changes in the hypothalamic–pituitary–adrenal axis and shifting sex-hormone levels. These biological transitions may make the developing brain particularly sensitive to environmental stress, poor sleep, diet, infection and chronic inflammation. The review argues that gut microbiota dysbiosis—the disruption of the composition or function of microbial communities in the intestine—could interact with these vulnerabilities.
The human gut contains trillions of microorganisms, including bacteria, fungi and other microbes that help digest food, produce metabolites and regulate immune activity. A balanced microbial ecosystem contributes to the production of short-chain fatty acids, such as acetate, propionate and butyrate, which can affect intestinal barrier integrity, immune signaling and nervous-system function. When microbial diversity or metabolic activity changes, the resulting chemical environment may alter communication between the gut and the brain. The authors describe this process as part of the microbiota–gut–brain axis, a two-way network involving neural, endocrine, immune and metabolic pathways.
One route of communication involves the stress-response system. Psychological stress can influence gut movement, intestinal permeability and microbial composition through the release of stress hormones. In turn, microbial metabolites and inflammatory signals may affect the hypothalamic–pituitary–adrenal axis, which coordinates the body’s response to stress. Persistent activation of this system can increase circulating cortisol and may contribute to sleep disruption, emotional instability and changes in neural plasticity. During adolescence, when stress-regulation circuits are still maturing, this feedback loop could become especially important in the development or persistence of depressive symptoms.
Inflammation is another central mechanism discussed in the review. A weakened intestinal barrier may allow microbial products, including components of bacterial cell walls, to enter the circulation and stimulate immune receptors. This can promote the release of cytokines—signaling proteins that coordinate inflammation—which may influence brain function even without direct infection of nervous tissue. Inflammatory signals can affect neurotransmitter metabolism, reduce synaptic adaptability and alter the activity of brain regions involved in motivation and emotion. The authors connect these processes to the possibility that gut dysbiosis may contribute to an inflammation-linked subtype of depression, although the biological relationship is not expected to be identical in every adolescent.
The review also highlights microbial involvement in neurotransmitter and neuromodulator pathways. Gut microorganisms can influence the availability and metabolism of compounds related to serotonin, dopamine, gamma-aminobutyric acid and glutamate. Serotonin, for example, is largely produced in the gastrointestinal tract, where it regulates intestinal function, but gut-derived signals can also affect the precursors and pathways involved in serotonin activity in the brain. Microbes may additionally modify tryptophan metabolism, directing this amino acid toward kynurenine and other metabolites that can influence immune signaling and neuronal function. These biochemical routes provide plausible explanations for how intestinal changes might be associated with mood, cognition and reward processing.
The researchers emphasize that gut microbiota patterns linked with depression should not be interpreted as a simple “depression bacteria” signature. Microbial communities vary with diet, geography, medication use, age, sleep, physical activity and socioeconomic conditions. Antibiotics and other drugs can produce major shifts, while depressive symptoms themselves may change eating habits, movement and daily routines, creating reverse causation. Many existing studies are also observational, meaning they can identify associations but cannot prove that dysbiosis causes depression. Differences in sample collection, sequencing technology and analytical methods further complicate comparisons between studies.
Despite these challenges, the review surveys a growing range of microbiota-targeted therapeutic strategies. These include dietary interventions designed to increase fiber and plant-based substrates for beneficial microbial fermentation, probiotic and prebiotic formulations, synbiotics that combine both approaches, and postbiotics containing microbial metabolites or cell-derived components. Fecal microbiota transplantation and precision microbial therapies are also discussed as emerging possibilities, although their safety, effectiveness and appropriate use in adolescents require careful investigation. Any clinical application would need to account for developmental stage, psychiatric risk, nutritional status and the possibility of interactions with existing antidepressant treatments.
The authors ultimately call for more rigorous research combining microbiology, psychiatry, neuroscience and endocrinology. Future studies may need large, longitudinal cohorts that follow young people before, during and after depressive episodes while measuring diet, medication, sleep, stress hormones, immune markers, microbial genes and metabolites. Randomized clinical trials will be essential for determining whether changing the microbiota can reduce depressive symptoms, rather than merely accompanying improvement produced by other treatments. For now, the gut–brain connection offers a promising biological framework, but not a standalone diagnosis or cure. The review’s central message is that adolescent depression is a complex disorder, and understanding the microbial ecosystem within the body could eventually help make prevention and treatment more personalized.
Subject of Research: The relationship between adolescent depression, gut microbiota dysbiosis, gut–brain communication mechanisms and microbiota-targeted therapeutics.
Article Title: Adolescent depression and gut microbiota dysbiosis: characteristics, mechanisms, and microbiota-targeted therapeutics
Article References: Zi, Z., Liu, L., Zhou, J. et al. “Adolescent depression and gut microbiota dysbiosis: characteristics, mechanisms, and microbiota-targeted therapeutics.” Translational Psychiatry (2026). https://doi.org/10.1038/s41398-026-04330-w
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41398-026-04330-w
Keywords: adolescent depression, gut microbiota, dysbiosis, microbiota–gut–brain axis, inflammation, stress response, neurotransmitters, probiotics, prebiotics, microbiota-targeted therapeutics
